Latest News about BMY
Recent news which mentions BMY
2 Ridiculously Cheap Growth Stocks to Buy
October 02, 2021
From Motley Fool
Bristol Myers Squibb: Should You Buy the Dip?
October 02, 2021
From Motley Fool
The Daily Biotech Pulse: Merck Rallies On Antiviral Pill Data, Gilead Files For Yescarta Label Expansion, Exscientia IPO
October 01, 2021
From Benzinga
From Motley Fool
Merck Seals Acceleron Pharma Deal For $180/Share: Highlights
September 30, 2021
From Benzinga
These 3 Top Healthcare Stocks Are Screaming Buys Right Now
September 29, 2021
From Motley Fool
AstraZeneca's Saphnelo For Lupus Treatment Approved In Japan
September 28, 2021
From Benzinga
Merck Reportedly Lead Bidder In $11B Acceleron Buyout: WSJ
September 28, 2021
From Benzinga
3 Big Pharma Stocks Wall Street Thinks Could Soar By At Least 30%
September 28, 2021
From Motley Fool
Merck nears deal for rare-disease-drug maker Acceleron
September 28, 2021
From MarketWatch
Thinking of Buying Pfizer Stock? Here's What You Need to Know
September 27, 2021
From Motley Fool
Acceleron In Advanced $11B Buyout Talks: Bloomberg
September 27, 2021
From Benzinga
3 No-Brainer Stocks to Invest $200 In Right Now
September 27, 2021
From Motley Fool
Is Now a Good Time to Buy Moderna Stock?
September 26, 2021
From Motley Fool
Why Acceleron Pharma Stock Jumped This Week
September 25, 2021
From Motley Fool
4 Stocks Insiders Are Selling
September 23, 2021
From Benzinga
5 Brand-Name Stocks to Buy Hand Over Fist if the Market Is Tumbling
September 23, 2021
From Motley Fool
Investors Cheer Onconova's Rigosertib Combo Data In Lung Cancer Setting
September 22, 2021
From Benzinga
3 Cheap Healthcare Stocks to Buy Right Now
September 22, 2021
From InvestorPlace
Mirati Unveils Long-term Survival Data For Sitravatinib/Nivolumab Combo In Lung Cancer Patients
September 20, 2021
From Benzinga
The Week Ahead In Biotech (Sept. 19-25): Incyte, Verrica FDA Decisions And Conference Presentations In The Spotlight
September 19, 2021
From Benzinga
With Prothena Up Over 500% This Year, Is It Too Late to Get in?
September 18, 2021
From Motley Fool
From Benzinga
Gritstone Presents Data From Individualized Neoantigen Immunotherapy In Colorectal Cancer
September 17, 2021
From Benzinga
These Industries Stand To Benefit From The Infrastructure Bill — And These Companies Are Lobbying Against It
September 16, 2021
From Benzinga
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.